Skip to main content
Premium Trial:

Request an Annual Quote

TrimGen to Debut New Warfarin-Dosing IVD In 'Near Future' as FDA Clearance Nears

This article has been updated from a previous version to clarify statements from a TrimGen official about the company's expectations regarding FDA approval for its test. The company said that it has not yet received official notification from the FDA, and that it expects the test to clear in the near future, rather than by the end of the month, as the firm previously stated. 
TrimGen expects the US Food and Drug Administration to clear as an in vitro diagnostic its warfarin-dosing test “in the near future,” James Doherty, TrimGen product specialist, told Pharmacogenomics Reporter this week.
Maryland-based TrimGen, which submitted its 510(k) application for the eQ-PCR LightCycler Warfarin Genotyping Kit in December 2007, said it plans to differentiate its test from rivals’ products based on its 1.5-hour turn-around and relative ease of use.
TrimGen has looked at the clinical and analytical validity of the test in a 170-patient-sample study at three sites — Virginia Commonwealth University, Oregon Health University, and TrimGen Laboratories — where approximately 2,900 tests were performed. Doherty said the diagnostic, which is based on Roche's eQ-PCR LightCycler platform, had 100-percent agreement with bi-directional sequencing.
TrimGen also markets the Mutector II Warfarin Genotyping Test kit, which analyzes samples using an ABI capillary sequencer.
If cleared, the company’s LightCycler warfarin test will be the fifth such product to win regulatory approval in the US, behind those made by ParagonDx, AutoGenomics, Nanosphere, and Osmetech. There are also several homebrew assays marketed by Laboratory Corporation of America, Idaho Technology, and Clinical Data, among others.
TrimGen’s test is designed to detect what are generally believed to be the most clinically relevant genetic variations responsible for patient sensitivity to the anticoagulant: the CYP 2C9*2 (C430T), 2C9*3 (A1075C), and VKORC1 (-1639 G>A) mutations.

TrimGen plans to differentiate its test from competitors based on the fast turn-around time and ease of use of its product.

However, there are several competing products out on the market that offer testing for other mutations. For instance, Genelex’s homebrew Warfarin Target Dose Safety Test, based on Tm BioSciences’ Tag-It Universal Array platform, gauges CYP 2C9 *2, *3, *4, *5, *6, and VKORC1 (-1639 G>A) mutations. Nanosphere’s FDA-approved Warfarin Metabolism Nucleic Acid Test gauges CYP 2C9 *2, *3, as well as VKORC1 (-1639 G>A) and (1173C>T).
Meanwhile, AutoGenomics boasts that its INFINITI assay detects 15 2C9 and VKORC1 variants, more than any other company in the market. Among the 15 variants the INFINITI assay detects, several polymorphisms will be specific to particular ethnicities – such as the *4 variant identified exclusively among Japanese people and the 8773 SNPs in VKORC1 found in 21 percent of African Americans [see PGx Reporter 10-10-2007].
And although TrimGen is touting a run time of 1.5 hours for its test, there is competition on this front as well, since ParagonDx's Rapid Genotyping Assay claims to complete the process in less than 30 minutes and Nanosphere's Verigene System takes 1.5 hours. In comparison, AutoGenomics' Infiniti Warfarin XP assay requires 10.6 hours. Third Wave's 96-well platform and Luminex's Tag-It assay, which are not FDA cleared, report run times of around three hours.
Ultimately, price stands to be one of the most important differentiating points, particularly since questions of clinical utility have kept major insurers from reimbursing gene-based warfarin-dosing tests [see PGx Reporter 12-19-2007].
Currently marketed warfarin sensitivity tests range in price between $200 and $500 for each patient. TrimGen's assay has a list price of $960 for 16 patients.
“The kit list price is $960 and has reagents for 16 patient samples, which works out to be $60 per patient sample,” Doherty said. “What the laboratory charges beyond that is up to them.”
According to TrimGen’s Doherty, reimbursement discussion will be initiated by the laboratories using its kit. “Once we attain 510(k), assuming the lab doing the test is CLIA certified, they should already have a protocol in place for negotiating reimbursement schedules,” Doherty said.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.